JP6441313B2 - ドラベ症候群の処置における使用のためのフェンフルラミン - Google Patents

ドラベ症候群の処置における使用のためのフェンフルラミン Download PDF

Info

Publication number
JP6441313B2
JP6441313B2 JP2016511083A JP2016511083A JP6441313B2 JP 6441313 B2 JP6441313 B2 JP 6441313B2 JP 2016511083 A JP2016511083 A JP 2016511083A JP 2016511083 A JP2016511083 A JP 2016511083A JP 6441313 B2 JP6441313 B2 JP 6441313B2
Authority
JP
Japan
Prior art keywords
fenfluramine
day
patient
oral solution
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016511083A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518387A (ja
JP2016518387A5 (enExample
Inventor
バートン クーレマンス
バートン クーレマンス
リーヴェン ラガエ
リーヴェン ラガエ
Original Assignee
カトリック ユニバーシテイト ルーベン
カトリック ユニバーシテイト ルーベン
ユニバーシティー ホスピタル アントワープ
ユニバーシティー ホスピタル アントワープ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50729472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6441313(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by カトリック ユニバーシテイト ルーベン, カトリック ユニバーシテイト ルーベン, ユニバーシティー ホスピタル アントワープ, ユニバーシティー ホスピタル アントワープ filed Critical カトリック ユニバーシテイト ルーベン
Publication of JP2016518387A publication Critical patent/JP2016518387A/ja
Publication of JP2016518387A5 publication Critical patent/JP2016518387A5/ja
Application granted granted Critical
Publication of JP6441313B2 publication Critical patent/JP6441313B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
JP2016511083A 2013-05-03 2014-05-01 ドラベ症候群の処置における使用のためのフェンフルラミン Active JP6441313B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/887,014 US9549909B2 (en) 2013-05-03 2013-05-03 Method for the treatment of dravet syndrome
US13/887,014 2013-05-03
PCT/EP2014/058954 WO2014177676A1 (en) 2013-05-03 2014-05-01 Fenfluramine for use in the treatment of dravet syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018218149A Division JP6655156B2 (ja) 2013-05-03 2018-11-21 ドラベ症候群の処置における使用のためのフェンフルラミン

Publications (3)

Publication Number Publication Date
JP2016518387A JP2016518387A (ja) 2016-06-23
JP2016518387A5 JP2016518387A5 (enExample) 2017-05-25
JP6441313B2 true JP6441313B2 (ja) 2018-12-19

Family

ID=50729472

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016511083A Active JP6441313B2 (ja) 2013-05-03 2014-05-01 ドラベ症候群の処置における使用のためのフェンフルラミン
JP2018218149A Active JP6655156B2 (ja) 2013-05-03 2018-11-21 ドラベ症候群の処置における使用のためのフェンフルラミン
JP2020014754A Active JP6966584B2 (ja) 2013-05-03 2020-01-31 ドラベ症候群の処置における使用のためのフェンフルラミン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018218149A Active JP6655156B2 (ja) 2013-05-03 2018-11-21 ドラベ症候群の処置における使用のためのフェンフルラミン
JP2020014754A Active JP6966584B2 (ja) 2013-05-03 2020-01-31 ドラベ症候群の処置における使用のためのフェンフルラミン

Country Status (17)

Country Link
US (13) US9549909B2 (enExample)
EP (2) EP2991637B1 (enExample)
JP (3) JP6441313B2 (enExample)
AU (4) AU2014261329B2 (enExample)
BR (1) BR112015027282A8 (enExample)
CA (1) CA2909335C (enExample)
CY (1) CY1124298T1 (enExample)
DK (2) DK2991637T3 (enExample)
ES (2) ES2666657T3 (enExample)
HR (1) HRP20210819T1 (enExample)
HU (1) HUE054577T2 (enExample)
LT (1) LT3329909T (enExample)
NO (1) NO3092234T3 (enExample)
PL (2) PL2991637T3 (enExample)
PT (2) PT3329909T (enExample)
SI (1) SI3329909T1 (enExample)
WO (1) WO2014177676A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
EP3201808B1 (en) * 2014-09-29 2021-10-20 Zogenix International Limited Control system for control of distribution of medication
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
AU2016222804C1 (en) 2015-02-25 2021-10-14 The Regents Of The University Of California 5HT agonists for treating disorders
JP6668045B2 (ja) * 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
MX389927B (es) * 2015-08-24 2025-03-20 Zogenix International Ltd Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
KR102422625B1 (ko) 2015-10-09 2022-07-20 유니버시티 오브 사우스앰톤 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
KR102604132B1 (ko) 2015-12-14 2023-11-17 콜드스프링하버러보러토리 상염색체 우성 정신 지체 5 및 드라베 증후군의 치료를 위한 안티센스 올리고머
CA3007286A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
EP3393470B1 (en) 2015-12-22 2021-01-20 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
MX2019001799A (es) 2016-08-24 2019-06-13 Zogenix International Ltd Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US20180092864A1 (en) * 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
JP2019535760A (ja) * 2016-11-22 2019-12-12 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． フルピルチンを用いた発達障害および／または発作性障害の処置方法
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
EP3609481A4 (en) * 2017-04-13 2021-05-26 Ovid Therapeutics Inc. DEVELOPMENTAL ENCEPHALOPATHY TREATMENT METHODS
JP2020519594A (ja) * 2017-05-09 2020-07-02 ゾゲニクス インターナショナル リミテッド フェンフルラミンを用いるドゥーゼ症候群の治療方法
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
SG11202001590RA (en) 2017-08-25 2020-03-30 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
US20190091177A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Method of treating selected patient population experiencing dravet syndrome
WO2019067413A1 (en) * 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
EP3788169A4 (en) 2018-05-04 2022-08-10 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
WO2019216919A1 (en) * 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
US20210113495A1 (en) * 2018-07-10 2021-04-22 Zogenix International Limited Method of treating epilepsy or epileptic encephalopathy with fenfluramine in patients without pulmonary hypertension
BR112021001135A2 (pt) * 2018-07-27 2021-04-20 Xenon Pharmaceuticals Inc. compostos e composições farmacêuticas para tratar epilepsia ou transtorno convulsivo epiléptico
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
JP2022521446A (ja) * 2019-02-25 2022-04-07 ゾゲニクス インターナショナル リミテッド 発作制御を改善するための製剤
CN111944835B (zh) * 2019-05-14 2022-03-29 南通大学 一种突变型gabrg2转基因斑马鱼癫痫模型的构建方法及应用
EP4021454A1 (en) * 2019-08-30 2022-07-06 Research Institute at Nationwide Children's Hospital Copper-atsm for treating neurodegenerative disorders associated with mitochondrial dysfunction
JP2022548892A (ja) * 2019-09-17 2022-11-22 ゾゲニクス インターナショナル リミテッド てんかん患者をフェンフルラミンで治療する方法
US20210299064A1 (en) 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
MX2022014151A (es) 2020-05-11 2022-11-30 Stoke Therapeutics Inc Oligomeros antisentido de opa1 para tratamiento de afecciones y enfermedades.
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
WO2023101866A1 (en) * 2021-12-01 2023-06-08 Zogenix International Limited Fenfluramine for treatment of conditions associated with spreading depolarization

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR104F (enExample) 1960-11-05
US3117160A (en) 1961-07-27 1964-01-07 Pfizer & Co C Aralkylamines
US3198834A (en) 1964-07-27 1965-08-03 Snc Science Union Et Compagnie Optical isomers of trifluoromethylated phenethylamines
GB1254332A (en) 1969-02-27 1971-11-17 Science Union & Cie Amino acids and their derivatives and processes for preparing them
DE2143204C3 (de) 1971-08-28 1979-09-27 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis
DE2150399A1 (de) 1971-10-09 1973-04-12 Hoechst Ag Neue oxime
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
US4452815A (en) 1980-06-16 1984-06-05 Massachusetts Institute Of Technology Method of utilizing d,l-fenfluramine for modifying feeding behavior
US4309445A (en) 1980-06-16 1982-01-05 Massachusetts Institute Of Technology d-Fenfluramine for modifying feeding behavior
DE3717434C1 (de) 1987-05-23 1988-09-15 Degussa Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril
US4857553A (en) 1987-08-06 1989-08-15 A. H. Robins Company, Incorporated Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
KR890003368A (ko) 1987-08-06 1989-04-14 원본미기재 특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법
HU204497B (en) 1989-10-09 1992-01-28 Chinoin Gyogyszer Es Vegyeszet Process for producing phenfluramine
IT1238686B (it) 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
FR2663539B1 (fr) 1990-06-22 1994-10-07 Adir Utilisation de la d-fenfluramine pour l'obtention de medicaments destines au traitement des deficiences immunitaires chez le sujet age.
FR2684552B1 (fr) 1991-12-06 1995-04-28 Adir Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
FR2685204B1 (fr) 1991-12-19 1995-06-16 Palmer Research Compositions pharmaceutiques pour l'administration transcutanee de la fenfluramine.
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
JP3342491B2 (ja) 1993-08-06 2002-11-11 ファルマシア・アンド・アップジョン・カンパニー 選択的ドーパミンｄ３リガンドとしての２−アミノインダン類
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5412102A (en) 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
ES2157330T3 (es) 1994-06-03 2001-08-16 Thejmde Trust Composicion que comprende aril-alquil-amina meta substituida, usos terapeuticos y diagnosticos.
IT1298349B1 (it) 1996-05-29 2000-01-05 Alfa Chem Ital Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina
IT1292885B1 (it) 1997-04-28 1999-02-11 Alfa Chem Ital Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina.
EP0920864A1 (en) 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
US20020098175A1 (en) 1998-06-16 2002-07-25 Zohoungbogbo Mathias C. Dietetic food composition and dietetic method using such composition
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
CA2355293C (en) 1998-12-23 2005-08-16 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7124031B1 (en) 2000-05-11 2006-10-17 Medco Health Solutions, Inc. System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
AU2001275095A1 (en) 2000-07-17 2002-01-30 Opt-E-Scrip, Inc. Single-patient drug trials used with accumulated database
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
ES2339339T3 (es) 2001-06-22 2010-05-19 Universite Catholique De Louvain Perlas o capsulas de hidrogel como medios artificiales para la oviposicion de insectos y la cria de endoparasitoides.
NZ530889A (en) 2001-07-31 2005-03-24 Wyeth Corp Use of sucralose as a sweetening agent combined with pH modulation of chemical formulations generates enhanced taste-masking effects
AUPR732601A0 (en) 2001-08-28 2001-09-20 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of amines such as ephedrine and inter mediates
CN100350968C (zh) 2001-09-24 2007-11-28 皇家创新有限公司 饮食行为的改进
RU2317104C2 (ru) 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
US6599901B1 (en) 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
WO2003082191A2 (en) 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
WO2005004865A1 (en) 2003-07-08 2005-01-20 Georg-August-Universität Göttingen Use of 5-ht4(a)-serotonin receptor agonists
GB0410266D0 (en) 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
US20050260610A1 (en) 2004-05-20 2005-11-24 Kurtz Richard E Method for diagnosing and prescribing a regimen of therapy for human health risk
US9820658B2 (en) 2006-06-30 2017-11-21 Bao Q. Tran Systems and methods for providing interoperability among healthcare devices
AU2005286672B2 (en) 2004-09-23 2009-03-12 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of childhood behavioral disorders
CN100567252C (zh) 2004-10-11 2009-12-09 俞锋 盐酸芬氟拉明原料药和片剂及其制备方法
CN101193588A (zh) 2005-03-21 2008-06-04 海尔思-斯玛特有限公司 连续血压监测的系统
CN101257889A (zh) 2005-05-25 2008-09-03 詹森药业有限公司 托吡酯的儿科制剂
WO2006133199A2 (en) 2005-06-06 2006-12-14 University Of South Florida Treatment with sigma receptor agonists post-stroke
CA2612180A1 (en) 2005-06-16 2006-12-21 Bionomics Limited Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
EP1937255A4 (en) 2005-09-14 2013-06-26 Univ Witwatersrand Jhb PHARMACEUTICAL COMPOSITION
CA2622967A1 (en) 2005-09-19 2007-03-29 Biolert Ltd. A system and method for detecting an epileptic event
EP1958111A4 (en) 2005-11-29 2009-07-08 Childrens Hosp Medical Center OPTIMIZATION AND INDIVIDUALIZATION OF THE SELECTION AND DOSAGE OF MEDICAMENTS
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007079181A2 (en) 2005-12-28 2007-07-12 Neurovista Corporation Methods and systems for recommending an action to a patient for managing epilepsy and other neurological disorders
RU2008135692A (ru) 2006-02-06 2010-03-20 Новартис АГ (CH) Комбинация органический х-соединений
DE102006030113B4 (de) 2006-06-28 2009-02-12 Chemische Fabrik Budenheim Kg Graphitfreier Hochtemperatur-Schmierstoff
EP2053961A4 (en) 2006-08-09 2013-05-01 Biogen Idec Inc METHOD FOR DISPENSING A MEDICAMENT
WO2008025148A1 (en) 2006-08-31 2008-03-06 The Governors Of The University Of Alberta Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators
WO2008095095A2 (en) 2007-01-31 2008-08-07 Quintiles Transnational Corp. Methods and systems for allocating representatives to sites in clinical trials
EP3135282A1 (en) 2007-02-08 2017-03-01 Biogen MA Inc. Neuroprotection in demyelinating diseases
JP2010520162A (ja) 2007-02-28 2010-06-10 スミスクライン ビーチャム コーポレーション ステアロイル−ＣｏＡデサチュラーゼ阻害剤であるチアジアゾール誘導体
JP2011507800A (ja) 2007-12-26 2011-03-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 癲癇、精神障害、または感覚器官の障害のためのａｍｐａ受容体アンタゴニスト
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US20110207718A1 (en) 2008-08-06 2011-08-25 Gosforth Centre (Holdings) Pty Ltd. Compositions and methods for treating psychiatric disorders
WO2010020585A1 (en) 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
SI2331210T1 (sl) 2008-09-05 2014-10-30 Gruenenthal Gmbh Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika
US8386274B1 (en) 2008-09-17 2013-02-26 Mckesson Financial Holdings Limited Systems and methods for a prescription safety network utilizing eligibility verification transactions
MX2011003695A (es) 2008-10-09 2011-08-17 A F S P A Aziende Chimiche Riunite Angelini Francesco A C R Formulacion farmaceutica liquida con contenido de paracetamol.
EP2355818A4 (en) 2008-10-10 2012-04-11 Us Of America As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Inst Of Res METHOD AND COMPOSITIONS FOR TREATING THE STATUS EPILEPTICUS AND STATUS EPILEPTICUS CAUSING ATTACHMENTS
TWI424832B (zh) 2008-12-15 2014-02-01 Proteus Digital Health Inc 與身體有關的接收器及其方法
US20120065999A1 (en) 2009-03-09 2012-03-15 Celgene Corporation Device for Delivering a Drug to a Patient While Restricting Access to the Drug by Patients for Whom the Drug May Be Contraindicated and Methods for Use Thereof
AU2010236404B2 (en) 2009-04-15 2016-11-03 Research Triangle Institute Monoamine reuptake inhibitors
WO2010124137A1 (en) 2009-04-22 2010-10-28 Millennium Pharmacy Systems, Inc. Pharmacy management and administration with bedside real-time medical event data collection
US9453027B2 (en) 2009-07-27 2016-09-27 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
UY33173A (enExample) 2010-01-08 2011-07-29 Eurand Inc
CA2792507C (en) 2010-03-09 2018-05-22 Perceptimed, Inc. Medication verification and dispensing
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
JP2011221623A (ja) 2010-04-06 2011-11-04 Kakimori Suri 在宅診療支援システム及び方法
AU2011255276B2 (en) 2010-05-21 2016-09-22 Research Triangle Institute Phenylmorpholines and analogues thereof
EP2399513B1 (en) 2010-06-23 2017-01-04 Qatar University Qstp-B System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms
JP2013535469A (ja) 2010-07-30 2013-09-12 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｙｐ３ａ薬物代謝の阻害
SG10201506874UA (en) 2010-09-01 2015-10-29 Arena Pharm Inc Modified-release dosage forms of 5-ht2c agonists useful for weight management
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
US20140030343A1 (en) 2010-10-26 2014-01-30 Alpharma Pharmaceuticals Llc Formulations and Methods for Attenuating Respiratory Depression Induced by Opioid Overdose
RU103209U1 (ru) 2010-10-29 2011-03-27 Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" Клиническая информационная система
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
US10183008B2 (en) 2011-02-09 2019-01-22 University Of South Carolina Treatment of prolonged status epilepticus
JP5693325B2 (ja) 2011-03-29 2015-04-01 小林クリエイト株式会社 健診結果出力システム及び健診結果出力プログラム
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US10092750B2 (en) 2011-11-11 2018-10-09 Neuroenabling Technologies, Inc. Transcutaneous neuromodulation system and methods of using same
US20140348966A1 (en) 2011-12-22 2014-11-27 Onesmo B. Balemba Garcinia buchananii baker compounds, compositions and related methods
CA2862816A1 (en) 2012-01-27 2013-08-01 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
US9346798B2 (en) 2012-02-13 2016-05-24 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US20130218586A1 (en) 2012-02-21 2013-08-22 Frederic J. Huser Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status
JP6075973B2 (ja) 2012-06-04 2017-02-08 富士通株式会社 健康状態判定装置およびその作動方法
BR112015011213A2 (pt) 2012-11-15 2017-08-29 Galleon Pharmaceuticals Inc Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição.
WO2014106825A2 (en) 2013-01-06 2014-07-10 Jonathan Rabinowitz Methods and devices for identifying improper medical reporting
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
JP6574769B2 (ja) 2013-07-25 2019-09-11 ニューレン ファーマシューティカルズ リミテッド 二環式化合物ならびに自閉症スペクトラム障害および神経発達障害の治療におけるそれらの使用方法
PT3035926T (pt) 2013-08-19 2020-09-01 Univ California Compostos e métodos para tratar um distúrbio epiléptico
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US20150141415A1 (en) 2013-11-20 2015-05-21 Omonike Arike Olaleye Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases
CN103886415A (zh) 2014-03-25 2014-06-25 北京蝶禾谊安信息技术有限公司 药品管理方法和装置
US20170089924A1 (en) 2014-04-22 2017-03-30 Tohoku University Method of testing for pulmonary hypertension
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
WO2016003966A1 (en) 2014-06-30 2016-01-07 University Of Cincinnati Non-invasive detection of spreading depolarization using scalp electroencephalography
EP3201808B1 (en) 2014-09-29 2021-10-20 Zogenix International Limited Control system for control of distribution of medication
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
CA3254865A1 (en) 2015-02-06 2025-05-28 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
AU2016222804C1 (en) 2015-02-25 2021-10-14 The Regents Of The University Of California 5HT agonists for treating disorders
US10292996B2 (en) 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
CN104800168A (zh) 2015-04-08 2015-07-29 石家庄四药有限公司 司替戊醇干混悬剂及其制备方法
JP6668045B2 (ja) 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
US10471087B2 (en) 2015-06-17 2019-11-12 The Trustees Of Columbia University In The City Of New York Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes
JP6731427B2 (ja) 2015-06-30 2020-07-29 ネウラッド リミテッドＮｅｕｒａｄ Ｌｔｄ． 新規の呼吸制御調節化合物、およびこれを製造し、かつ使用する方法
WO2017015309A1 (en) 2015-07-22 2017-01-26 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
MX389927B (es) 2015-08-24 2025-03-20 Zogenix International Ltd Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
US20170071949A1 (en) 2015-09-14 2017-03-16 Zogenix International Limited Combination treatment of specific forms of epilepsy
US20220193082A1 (en) 2015-09-14 2022-06-23 Zogenix International Limited Combination treatment of specific forms of epilepsy
EP3170807B1 (en) 2015-11-23 2019-12-11 Frau Pharma S.r.l. New method for synthesis of fenfluramine
EP3393470B1 (en) 2015-12-22 2021-01-20 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
CA3007286A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
CN108699312B (zh) 2016-01-14 2021-04-20 Ａｇｃ株式会社 含氟树脂溶液、含氟树脂溶液的制造方法、涂料组合物及涂装物品
ES2882175T3 (es) 2016-03-28 2021-12-01 Takeda Pharmaceuticals Co Compuestos para su uso en el tratamiento de la hipertensión pulmonar
MX2019001799A (es) 2016-08-24 2019-06-13 Zogenix International Ltd Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.
US20190083425A1 (en) 2016-08-24 2019-03-21 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
US20180092864A1 (en) 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
IL310065A (en) 2017-02-08 2024-03-01 Ovid Therapeutics Inc Methods for treating seizure disorders and Prader-Willi syndrome
JP2020519594A (ja) 2017-05-09 2020-07-02 ゾゲニクス インターナショナル リミテッド フェンフルラミンを用いるドゥーゼ症候群の治療方法
WO2019067413A1 (en) 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US20190091177A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Method of treating selected patient population experiencing dravet syndrome
US20190247333A1 (en) 2017-09-26 2019-08-15 Zogenix International Limited Method of reduction in convulsive seizure frequency
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
MX2020010994A (es) 2018-04-18 2021-01-08 Univ Columbia Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial.
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
US20210113495A1 (en) 2018-07-10 2021-04-22 Zogenix International Limited Method of treating epilepsy or epileptic encephalopathy with fenfluramine in patients without pulmonary hypertension
BR112021001135A2 (pt) 2018-07-27 2021-04-20 Xenon Pharmaceuticals Inc. compostos e composições farmacêuticas para tratar epilepsia ou transtorno convulsivo epiléptico
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
US20210401776A1 (en) 2018-11-30 2021-12-30 Zogenix International Limited Method of treating refractory epilepsy syndromes using fenfluramine enantiomers
JP2022521446A (ja) 2019-02-25 2022-04-07 ゾゲニクス インターナショナル リミテッド 発作制御を改善するための製剤
US20210299064A1 (en) 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20220096514A1 (en) 2020-09-29 2022-03-31 Zogenix International Limited Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine
EP4395753A4 (en) 2021-09-01 2025-05-07 Zogenix International Limited Fenfluramine for treatment of demyelinating diseases and conditions
WO2023101866A1 (en) 2021-12-01 2023-06-08 Zogenix International Limited Fenfluramine for treatment of conditions associated with spreading depolarization

Also Published As

Publication number Publication date
JP2020063309A (ja) 2020-04-23
US10478442B2 (en) 2019-11-19
US9603814B2 (en) 2017-03-28
US20170151214A1 (en) 2017-06-01
AU2014261329A1 (en) 2015-11-05
JP6655156B2 (ja) 2020-02-26
JP6966584B2 (ja) 2021-11-17
US9549909B2 (en) 2017-01-24
AU2014261329B2 (en) 2019-02-21
AU2019203832B2 (en) 2020-10-15
US20170151194A1 (en) 2017-06-01
US9610260B2 (en) 2017-04-04
HRP20210819T1 (hr) 2021-08-20
PT3329909T (pt) 2021-05-14
US9603815B2 (en) 2017-03-28
EP3329909A1 (en) 2018-06-06
US10478441B2 (en) 2019-11-19
CA2909335A1 (en) 2014-11-06
JP2016518387A (ja) 2016-06-23
US20170151257A1 (en) 2017-06-01
HUE054577T2 (hu) 2021-09-28
BR112015027282A2 (pt) 2017-07-25
ES2666657T3 (es) 2018-05-07
US20220160727A1 (en) 2022-05-26
CY1124298T1 (el) 2022-07-22
ES2863929T3 (es) 2021-10-13
US20170151213A1 (en) 2017-06-01
US20140343162A1 (en) 2014-11-20
EP3329909B1 (en) 2021-03-17
US20140329908A1 (en) 2014-11-06
WO2014177676A1 (en) 2014-11-06
US12097206B2 (en) 2024-09-24
PT2991637T (pt) 2018-04-24
DK3329909T3 (da) 2021-04-19
AU2019203832A1 (en) 2019-06-20
JP2019048862A (ja) 2019-03-28
PL3329909T3 (pl) 2021-10-11
NO3092234T3 (enExample) 2018-07-14
LT3329909T (lt) 2021-07-12
EP2991637B1 (en) 2018-03-07
US20200030341A1 (en) 2020-01-30
US20210121479A1 (en) 2021-04-29
PL2991637T3 (pl) 2018-07-31
US20140343044A1 (en) 2014-11-20
EP2991637A1 (en) 2016-03-09
US20140343161A1 (en) 2014-11-20
CA2909335C (en) 2021-05-18
AU2019203448A1 (en) 2019-06-06
SI3329909T1 (sl) 2021-08-31
DK2991637T3 (en) 2018-05-07
AU2020267264A1 (en) 2020-12-17
US20160136114A1 (en) 2016-05-19
US20170151259A1 (en) 2017-06-01
BR112015027282A8 (pt) 2019-12-24
AU2019203448B2 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
JP6441313B2 (ja) ドラベ症候群の処置における使用のためのフェンフルラミン
KR102615486B1 (ko) 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법
HK1256346A1 (en) Fenfluramine for use in the treatment of dravet syndrome
HK1256346B (en) Fenfluramine for use in the treatment of dravet syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170406

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180814

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181022

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181121

R150 Certificate of patent or registration of utility model

Ref document number: 6441313

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250